Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hodgson, N.
Right arrow Articles by Holliday, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hodgson, N.
Right arrow Articles by Holliday, R.
Related Collections
Right arrow Diagnosis
Annals of Surgical Oncology 8:133-137 (2001)
© 2001 Society of Surgical Oncology

ORIGINAL ARTICLES

A New Radiocolloid for Sentinel Node Detection in Breast Cancer

N. Hodgson, MD, P. Zabel, MSc, A.G. Mattar, MD, C.J. Engel, MD, D. Girvan, MD and R. Holliday, MD

From the Departments of Surgery (NH, CJE, RH) and Nuclear Medicine (PZ, AGM), London Health Sciences Center, University of Western Ontario, London, Ontario, Canada.

Correspondence: Address correspondence and reprint requests to: R. Holliday, MD, 375 South St, Victoria Campus, London Health Sciences Centre, London, Ontario, Canada N6A 4G5.

Background: The optimal radioactive tracer and technique for sentinel lymph node localization in breast cancer is yet to be determined. The dilemma of small particle size with dispersion to second echelon nodes versus failure of migration of larger radiocolloids needs to be resolved. A new radiocolloid preparation with particle size under 0.1 micron was developed with excellent primary/post lymphatic entrapment ratio.

Objective: To assess the feasibility of a new 99mTc radiocolloid cysteine-rhenium colloid in sentinel lymph node (SLN) localization for breast cancer.

Methods: Forty-seven patients with newly diagnosed T1 or T2 breast cancer underwent injection of 99mTc-labeled cysteine-rhenium colloid followed by lymphoscintigraphy. Same day SLN biopsy with patent blue dye and intraoperative gamma probe to identify SLNs were performed.

Results: SLN mapping and intraoperative localization were successful in 46/47 (98%) of patients. The blue dye radioactive tracer concordance was 94%. There was one false-negative in a patient with a nonpalpable tumor that underwent ultrasound-guided peritumoral radiocolloid injection.

Conclusions: 99mTc-cysteine-rhenium colloid is highly effective in identifying SLNs. It has the advantage of smaller particle size than sulfur colloid with easier lymphatic migration. It has a more neutral pH with less pain on injection and does not require filtration, thereby minimizing radiation exposure to technologists.

Key Words: Sentinel lymph node • Radiocolloid • Breast cancer






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the Society of Surgical Oncology.